Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications

被引：96

作者：

Barroso-Sousa, Romualdo ^{[1
]}

Metzger-Filho, Otto ^{[1
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Yawkey 1238, Boston, MA 02215 USA

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2016年 / 8卷 / 04期

关键词：

breast neoplasm; chemotherapy; invasive ductal carcinoma; invasive lobular carcinoma; letrozole; tamoxifen; TCGA; trastuzumab; NEOADJUVANT CHEMOTHERAPY; RECURRENCE SCORE; TAMOXIFEN; TRASTUZUMAB; EXPRESSION; LETROZOLE; BINDING; BENEFIT; CANCER; FOXA1;

D O I：

10.1177/1758834016644156

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological characteristics and responsiveness to systemic therapy. From the clinical standpoint, data suggest that ILC derives a distinct benefit from systemic therapy compared to IDC. In addition, comprehensive molecular analyses have been reported for ILCs, confirming that these tumors have specific genomic profiles compared to IDC. Despite these differences, clinical trials and practical clinical guidelines tend to treat BC as a single entity. Here we discuss these clinical and molecular data and their therapeutic implications.

引用

页码：261 / 266

页数：6

共 31 条

[1] Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma [J].

Bomeisl, Philip E. ;

Thompson, Cheryl L. ;

Harris, Lyndsay N. ;

Gilmore, Hannah L. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (12) :1546-1549

[2] Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1 [J].

Carroll, JS ;

Liu, XS ;

Brodsky, AS ;

Li, W ;

Meyer, CA ;

Szary, AJ ;

Eeckhoute, J ;

Shao, WL ;

Hestermann, EV ;

Geistlinger, TR ;

Fox, EA ;

Silver, PA ;

Brown, M .

CELL, 2005, 122 (01) :33-43

[3] Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer [J].

Ciriello, Giovanni ;

Gatza, Michael L. ;

Beck, Andrew H. ;

Wilkerson, Matthew D. ;

Rhie, Suhn K. ;

Pastore, Alessandro ;

Zhang, Hailei ;

McLellan, Michael ;

Yau, Christina ;

Kandoth, Cyriac ;

Bowlby, Reanne ;

Shen, Hui ;

Hayat, Sikander ;

Fieldhouse, Robert ;

Lester, Susan C. ;

Tse, Gary M. K. ;

Factor, Rachel E. ;

Collins, Laura C. ;

Allison, Kimberly H. ;

Chen, Yunn-Yi ;

Jensen, Kristin ;

Johnson, Nicole B. ;

Oesterreich, Steffi ;

Mills, Gordon B. ;

Cherniack, Andrew D. ;

Robertson, Gordon ;

Benz, Christopher ;

Sander, Chris ;

Laird, Peter W. ;

Hoadley, Katherine A. ;

King, Tari A. ;

Perou, Charles M. .

CELL, 2015, 163 (02) :506-519

[4] Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma? [J].

Conlon, Niamh ;

Ross, Dara S. ;

Howard, Jane ;

Catalano, Jeffrey P. ;

Dickler, Maura N. ;

Tan, Lee K. .

BREAST JOURNAL, 2015, 21 (05) :514-519

[5] Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes [J].

Cristofanilli, M ;

Gonzalez-Angulo, A ;

Sneige, N ;

Kau, SW ;

Broglio, K ;

Theriault, RL ;

Valero, V ;

Buzdar, AU ;

Kuerer, H ;

Buccholz, TA ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :41-48

[6] Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas [J].

Delpech, Y. ;

Coutant, C. ;

Hsu, L. ;

Barranger, E. ;

Iwamoto, T. ;

Barcenas, C. H. ;

Hortobagyi, G. N. ;

Rouzier, R. ;

Esteva, F. J. ;

Pusztai, L. .

BRITISH JOURNAL OF CANCER, 2013, 108 (02) :285-291

[7] Genomic Characterization of Primary Invasive Lobular Breast Cancer [J].

Desmedt, Christine ;

Zoppoli, Gabriele ;

Gundem, Gunes ;

Pruneri, Giancarlo ;

Larsimont, Denis ;

Fornili, Marco ;

Fumagalli, Debora ;

Brown, David ;

Rothe, Francoise ;

Vincent, Delphine ;

Kheddoumi, Naima ;

Rouas, Ghizlane ;

Majjaj, Samira ;

Brohee, Sylvain ;

Van Loo, Peter ;

Maisonneuve, Patrick ;

Salgado, Roberto ;

Van Brussel, Thomas ;

Lambrechts, Diether ;

Bose, Ron ;

Metzger, Otto ;

Galant, Christine ;

Bertucci, Francois ;

Piccart-Gebhart, Martine ;

Viale, Giuseppe ;

Biganzoli, Elia ;

Campbell, Peter J. ;

Sotiriou, Christos .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) :1872-+

[8] Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J].

Gianni, Luca ;

Dafni, Urania ;

Gelber, Richard D. ;

Azambuja, Evandro ;

Muehlbauer, Susanne ;

Goldhirsch, Aron ;

Untch, Michael ;

Smith, Ian ;

Baselga, Jose ;

Jackisch, Christian ;

Cameron, David ;

Mano, Max ;

Pedrini, Jose Luiz ;

Veronesi, Andrea ;

Mendiola, Cesar ;

Pluzanska, Anna ;

Semiglazov, Vladimir ;

Vrdoljak, Eduard ;

Eckart, Michael J. ;

Shen, Zhenzhou ;

Skiadopoulos, George ;

Procter, Marion ;

Pritchard, Kathleen I. ;

Piccart-Gebhart, Martine J. ;

Bell, Richard .

LANCET ONCOLOGY, 2011, 12 (03) :236-244

[9] Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer [J].

Huang, Bo ;

Omoto, Yoko ;

Iwase, Hirotaka ;

Yamashita, Hiroko ;

Toyama, Tatsuya ;

Coombes, Raoul Charles ;

Filipovic, Aleksandra ;

Warner, Margaret ;

Gustafsson, Jan-Ake .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (05) :1933-1938

[10] FOXA1 is a key determinant of estrogen receptor function and endocrine response [J].

Hurtado, Antoni ;

Holmes, Kelly A. ;

Ross-Innes, Caryn S. ;

Schmidt, Dominic ;

Carroll, Jason S. .

NATURE GENETICS, 2011, 43 (01) :27-U42

← 1 2 3 4 →